Professor Murray D. Mitchell

murray mitchell1

Professor Murray D. Mitchell, D.Phil, D.Sc, FRCOG, FRSNZ, is Professor of Child and Reproductive Health, Queensland University of Technology, located at The Centre for Child Health Research.

Professor Mitchell has received many distinctions including: Staines Medical Research Fellow, Exeter College, Oxford University; Presidents Achievement Award, Society for Gynecologic Investigation; Fellowship of the Royal Society of New Zealand (FRSNZ) and a James Cook Research Fellowship. He recently became FRCOG (Fellow of The Royal College of Obstetricians and Gynaecologists).

Professor Mitchell is a specialist in the mechanisms involved in labour and delivery.  He and Roberto Romero led the team that discovered the only known cause of premature labour: infection in the membranes lining the uterus.  Presently, he studies the potential roles of exosomes as diagnostics, prognostics and treatment vectors in a variety of situations.

He has held major grant funding from NIH (USA) and the MRC (UK): in total he has received over $50 million in research funding. Professor Mitchell has published over 500 peer reviewed papers and has an H index of 65.He holds two patents and has supervised 43 PhD students, 15 post-doctoral fellows, 6 MD Fellowship students and over 60 Honours / Masters students.


Presentation Title: Exosomes-Potential Prognostics Pitfalls and Therapeutics

Exosomes have exciting potential in both medical and agricultural arenas. Exosomes are widely touted as “liquid biopsies” but may have even greater potential for delivery of therapeutic agents. Diagnostics include cancer and pregnancy complications in women as well as fertility and resistance to infection or ticks in ungulates. Exosomes from milk are considered an extremely useful way to deliver drugs with no immunological response. Excitingly, exosomes not only can cross the blood-brain barrier and deliver potential therapeutics but also can provide increased potency compared to direct drug administration. Currently the pitfalls and problems that remain are due to the complexity of exosomal isolation procedures. Moreover, specific markers are not always available for the separation of exosome based on their cell/tissue of origin and we are mainly ignorant of targeting mechanisms. However, with improved targeting knowledge we might imagine a future in which genetic diseases are treated in utero with the need only of an injection into the maternal blood stream and nutritional supplementation delivered to babies and infants via nanovesicles in milk.